WO2011160541A1 - 托伐普坦固体分散体及其制备方法 - Google Patents
托伐普坦固体分散体及其制备方法 Download PDFInfo
- Publication number
- WO2011160541A1 WO2011160541A1 PCT/CN2011/075131 CN2011075131W WO2011160541A1 WO 2011160541 A1 WO2011160541 A1 WO 2011160541A1 CN 2011075131 W CN2011075131 W CN 2011075131W WO 2011160541 A1 WO2011160541 A1 WO 2011160541A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid dispersion
- tolvaptan
- water
- polyvinylpyrrolidone
- organic solvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012014251A MX2012014251A (es) | 2010-06-25 | 2011-06-02 | Dispersion solida de tolvaptan y su metodo de preparacion. |
CN2011800032986A CN102470178B (zh) | 2010-06-25 | 2011-06-02 | 托伐普坦固体分散体及其制备方法 |
BR112012031882A BR112012031882A2 (pt) | 2010-06-25 | 2011-06-02 | dispersão sólida de tolvaptan e seu método de preparação |
EP11797572.2A EP2586464B1 (en) | 2010-06-25 | 2011-06-02 | Tolvaptan solid dispersion and its preparation method |
US13/806,173 US9408915B2 (en) | 2010-06-25 | 2011-06-02 | Tolvaptan solid dispersion and its preparation method |
KR1020137000433A KR101815722B1 (ko) | 2010-06-25 | 2011-06-02 | 톨밥탄 고체 분산물 및 그의 제조 방법 |
JP2013515681A JP5991968B2 (ja) | 2010-06-25 | 2011-06-02 | トルバプタン固形分散剤及びその製造方法 |
AU2011269506A AU2011269506B2 (en) | 2010-06-25 | 2011-06-02 | Tolvaptan solid dispersion and its preparation method |
CA2801098A CA2801098C (en) | 2010-06-25 | 2011-06-02 | Tolvaptan solid dispersion and its preparation method |
RU2012157685/15A RU2579745C2 (ru) | 2010-06-25 | 2011-06-02 | Твердая дисперсия толваптана и способ ее получения |
TW100131876A TWI523842B (zh) | 2011-06-02 | 2011-09-05 | 托伐普坦固體分散體及其製備方法 |
HK12106725.5A HK1166005A1 (en) | 2010-06-25 | 2012-07-10 | Tolvaptan solid dispersion and its preparation method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102248840A CN102293734A (zh) | 2010-06-25 | 2010-06-25 | 托伐普坦固体分散体及其制备方法 |
CN201010224884.0 | 2010-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011160541A1 true WO2011160541A1 (zh) | 2011-12-29 |
Family
ID=45354575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/075131 WO2011160541A1 (zh) | 2010-06-25 | 2011-06-02 | 托伐普坦固体分散体及其制备方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9408915B2 (zh) |
EP (1) | EP2586464B1 (zh) |
JP (1) | JP5991968B2 (zh) |
KR (1) | KR101815722B1 (zh) |
CN (2) | CN102293734A (zh) |
AU (1) | AU2011269506B2 (zh) |
BR (1) | BR112012031882A2 (zh) |
CA (1) | CA2801098C (zh) |
HK (1) | HK1166005A1 (zh) |
MX (1) | MX2012014251A (zh) |
RU (1) | RU2579745C2 (zh) |
WO (1) | WO2011160541A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793706A (zh) * | 2012-08-14 | 2012-11-28 | 浙江华海药业股份有限公司 | 托伐普坦固体分散体的制备方法 |
WO2014133196A1 (en) * | 2013-03-01 | 2014-09-04 | Otsuka Pharmaceutical Co., Ltd. | Suspension for oral administration comprising amorphous tolvaptan |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6353061B2 (ja) | 2013-09-25 | 2018-07-04 | ダウ グローバル テクノロジーズ エルエルシー | 有機液体希釈剤及び特定のヒドロキシアルキルメチルセルロースを含む組成物 |
RU2017135502A (ru) * | 2015-03-12 | 2019-04-12 | Геркулес Ллк | Композиция для обработки нефтегазовых скважин, включающая гидроксиэтилцеллюлозу и сшитый поливинилпирролидон |
JP2018024628A (ja) * | 2016-08-02 | 2018-02-15 | ニプロ株式会社 | トルバプタンを含む非晶質固体分散体およびその製造方法 |
JP6838446B2 (ja) * | 2017-03-22 | 2021-03-03 | ニプロ株式会社 | トルバプタン製剤およびその製造方法 |
WO2020122670A1 (ko) * | 2018-12-14 | 2020-06-18 | 명인제약주식회사 | 톨밥탄을 포함하는 고체분산체 제조를 위한 약제학적 조성물 및 이의 제조방법 |
CN111888335A (zh) * | 2020-08-21 | 2020-11-06 | 福安药业集团重庆礼邦药物开发有限公司 | 一种托伐普坦的药物固体制剂及制备方法 |
CN113171344B (zh) * | 2021-04-12 | 2023-01-31 | 南京海纳医药科技股份有限公司 | 一种托伐普坦口服制剂及其制备方法 |
CN112972394B (zh) * | 2021-04-16 | 2022-09-13 | 浙江工业大学 | 一种姜黄素固体分散体及其机械力制备方法 |
KR20230133029A (ko) | 2022-03-10 | 2023-09-19 | 건양대학교산학협력단 | 톨밥탄을 포함하는 자가 유화 약물 전달 시스템 조성물 및 이의 제조방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1121241A (ja) * | 1997-07-03 | 1999-01-26 | Otsuka Pharmaceut Co Ltd | 固形製剤組成物 |
WO2008156217A2 (en) * | 2007-06-21 | 2008-12-24 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2167649C2 (ru) * | 1995-08-11 | 2001-05-27 | Ниссан Кемикал Индастриз, Лтд. | Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция |
JP2001335483A (ja) * | 2000-05-30 | 2001-12-04 | Nichiko Pharmaceutical Co Ltd | ニルバジピン含有製剤 |
ITMI20022748A1 (it) * | 2002-12-23 | 2004-06-24 | Eurand Int | Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione. |
ES2377121T3 (es) * | 2003-03-17 | 2012-03-22 | Japan Tobacco Inc. | Composiciones farmacéuticas de inhibidores de CETP |
WO2005103693A2 (en) * | 2004-04-27 | 2005-11-03 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
GB0428152D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
EA018811B1 (ru) * | 2006-03-20 | 2013-10-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом |
US8613946B2 (en) * | 2006-12-21 | 2013-12-24 | Isp Investment Inc. | Carotenoids of enhanced bioavailability |
WO2008081829A1 (ja) * | 2006-12-27 | 2008-07-10 | Astellas Pharma Inc. | 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe |
ES2406939T3 (es) * | 2007-10-19 | 2013-06-10 | Otsuka Pharmaceutical Co., Ltd. | Preparación farmacéutica de matriz sólida |
-
2010
- 2010-06-25 CN CN2010102248840A patent/CN102293734A/zh active Pending
-
2011
- 2011-06-02 BR BR112012031882A patent/BR112012031882A2/pt not_active IP Right Cessation
- 2011-06-02 WO PCT/CN2011/075131 patent/WO2011160541A1/zh active Application Filing
- 2011-06-02 CA CA2801098A patent/CA2801098C/en not_active Expired - Fee Related
- 2011-06-02 EP EP11797572.2A patent/EP2586464B1/en not_active Not-in-force
- 2011-06-02 AU AU2011269506A patent/AU2011269506B2/en not_active Ceased
- 2011-06-02 KR KR1020137000433A patent/KR101815722B1/ko active IP Right Grant
- 2011-06-02 MX MX2012014251A patent/MX2012014251A/es unknown
- 2011-06-02 CN CN2011800032986A patent/CN102470178B/zh active Active
- 2011-06-02 JP JP2013515681A patent/JP5991968B2/ja not_active Expired - Fee Related
- 2011-06-02 RU RU2012157685/15A patent/RU2579745C2/ru not_active IP Right Cessation
- 2011-06-02 US US13/806,173 patent/US9408915B2/en not_active Expired - Fee Related
-
2012
- 2012-07-10 HK HK12106725.5A patent/HK1166005A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1121241A (ja) * | 1997-07-03 | 1999-01-26 | Otsuka Pharmaceut Co Ltd | 固形製剤組成物 |
WO2008156217A2 (en) * | 2007-06-21 | 2008-12-24 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP2586464A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793706A (zh) * | 2012-08-14 | 2012-11-28 | 浙江华海药业股份有限公司 | 托伐普坦固体分散体的制备方法 |
CN102793706B (zh) * | 2012-08-14 | 2018-02-06 | 浙江华海药业股份有限公司 | 托伐普坦固体分散体的制备方法 |
WO2014133196A1 (en) * | 2013-03-01 | 2014-09-04 | Otsuka Pharmaceutical Co., Ltd. | Suspension for oral administration comprising amorphous tolvaptan |
CN105007897A (zh) * | 2013-03-01 | 2015-10-28 | 大塚制药株式会社 | 含有无定形托伐普坦的口服施用的混悬剂 |
KR20150122728A (ko) * | 2013-03-01 | 2015-11-02 | 오츠카 세이야쿠 가부시키가이샤 | 비정질 톨밥탄을 함유하는 경구 투여 현탁제 |
US20160000801A1 (en) * | 2013-03-01 | 2016-01-07 | Otsuka Pharmaceutical Co., Ltd. | Suspension for oral administration comprising amorphous tolvaptan |
JP2016509990A (ja) * | 2013-03-01 | 2016-04-04 | 大塚製薬株式会社 | 非晶質トルバプタンを含有する経口投与懸濁剤 |
CN105007897B (zh) * | 2013-03-01 | 2019-05-10 | 大塚制药株式会社 | 含有无定形托伐普坦的口服施用的混悬剂 |
TWI660748B (zh) * | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦(Tolvaptan)的懸浮液 |
KR102241643B1 (ko) * | 2013-03-01 | 2021-04-20 | 오츠카 세이야쿠 가부시키가이샤 | 비정질 톨밥탄을 함유하는 경구 투여 현탁제 |
US11759470B2 (en) | 2013-03-01 | 2023-09-19 | Otsuka Pharmaceutical Co., Ltd. | Suspension for oral administration comprising amorphous tolvaptan |
Also Published As
Publication number | Publication date |
---|---|
MX2012014251A (es) | 2013-01-18 |
JP5991968B2 (ja) | 2016-09-14 |
RU2579745C2 (ru) | 2016-04-10 |
AU2011269506A1 (en) | 2013-01-10 |
CA2801098A1 (en) | 2011-12-29 |
CN102470178B (zh) | 2013-06-05 |
US20130102588A1 (en) | 2013-04-25 |
EP2586464B1 (en) | 2018-07-25 |
AU2011269506B2 (en) | 2015-04-09 |
BR112012031882A2 (pt) | 2016-11-08 |
KR20130094281A (ko) | 2013-08-23 |
EP2586464A1 (en) | 2013-05-01 |
EP2586464A4 (en) | 2014-11-26 |
US9408915B2 (en) | 2016-08-09 |
KR101815722B1 (ko) | 2018-01-30 |
HK1166005A1 (en) | 2012-10-19 |
JP2013530189A (ja) | 2013-07-25 |
RU2012157685A (ru) | 2014-07-27 |
CA2801098C (en) | 2018-10-30 |
CN102293734A (zh) | 2011-12-28 |
CN102470178A (zh) | 2012-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011160541A1 (zh) | 托伐普坦固体分散体及其制备方法 | |
AU2008264445B2 (en) | Pharmaceutical solid preparation comprising benzazepines and production method thereof | |
WO2020249001A1 (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
US11382912B2 (en) | Controlled-release preparation | |
WO2013061338A1 (en) | Pharmaceutical compositions of silodosin | |
JP2007063217A (ja) | プランルカスト水和物含有錠及びその製造方法 | |
WO2020021110A1 (en) | Pharmaceutical composition of ticagrelor | |
JP2020518611A (ja) | 水溶解度及びバイオアベイラビリティが改善された組成物 | |
RU2007147953A (ru) | Фармацевтические рецептуры микронизированного (4-хлорфенил)[4-(4-пиридилметил)-фталазин-1-ила] и его солей с немедленным высвобождением и высоким содержанием лекарственного средства | |
JP3007387B2 (ja) | 徐放性製剤用基剤粉末 | |
TWI523842B (zh) | 托伐普坦固體分散體及其製備方法 | |
JP2019089758A (ja) | セレコキシブ含有錠剤における溶出性の改善方法 | |
JP6002869B1 (ja) | ジエノゲスト含有錠剤 | |
KR20080109463A (ko) | 페노피브레이트 함유 신규 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180003298.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11797572 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2801098 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10654/DELNP/2012 Country of ref document: IN Ref document number: MX/A/2012/014251 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2013515681 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011797572 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13806173 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137000433 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011269506 Country of ref document: AU Date of ref document: 20110602 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2012157685 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012031882 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012031882 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121213 |